

**Q1.** How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	12
1.2 Alpelisib (Piqray)	0
1.3 Fulvestrant (fulvestrant or Faslodex)	0
1.4 Palbociclib (Ibrance)	0
1.5 Ribociclib (Kisqali)	0

**Q2.** How many patients received abemaciclib (Verzenios) for **early breast cancer** in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Number patients treated
5

**Q3.** How many patients received abemaciclib (Verzenios) as **adjuvant treatment for early breast cancer** in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Number patients treated
N/A same as Q2

**Q4.** How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Treatment intent	Number patients treated
4.1 Curative	5
4.2 Palliative	7
4.3 Not known / stated	0

**Q5.** How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?

*Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Name of combination or monotherapy	Number patients treated
5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	2
5.2 Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	10* regimen prescribed, supply of AI may be from GP
5.3 Abemaciclib (Verzenois) + tamoxifen	0
5.4 Abemaciclib monotherapy	0
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)	2
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	6
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	32
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	0
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	3